About: Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $10.86 (-0.91%)
EIKNNASDAQEikon Therapeutics, Inc. Common Stock
Carregando status da lista de acompanhamento…
Eikon Therapeutics, Inc. Common Stock share price
EIKN price activity
Último preço
Variação (24h)
USD (%)
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/A
Último negócio
EIKN price performance
3,82%
5D
13,6%
1M
-27,6%
YTD
-27,6%
1Y
EIKN price fundamentals
N/D
Shares Issued
N/D
Earnings Per Share (EPS)
N/D
Dividends Per Share (DPS)
N/D
P/E Ratio
Price market cap
Cap. de mercado
N/A
Ranking em US-NASDAQ
N/ARanking do setor
N/Aquote.marketSignals